The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Publication | Closed Access

DOI

1.9K

Citations

References

2014

Year

Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, Sergey O. Kulyk, Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt,

The Lancet Oncology

Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacologyRandomised Phase 2Breast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchEndocrine-related Cancer